CreOSG Selected for National Project to Develop AI-Based Rotavirus and Dengue Virus Vaccines

CreOSG announced on August 7 that it has been selected for the 2025 3rd Biohealth R&D Project, specifically the national project for the "Personalized Diagnostic and Therapeutic Product Group" in the advanced bio sector, which is overseen by the Ministry of Trade, Industry and Energy.

This project aims to develop preventive vaccines for rotavirus and dengue virus by integrating artificial intelligence (AI)-based protein design with CreOSG's proprietary vaccine platform, as well as to conduct certain preclinical trials.

The project is a national advanced strategic industry research initiative focused on bio-vaccine specialized complexes, with a total government grant of 5.6 billion KRW to be provided over approximately five years starting in 2025. CreOSG, based in the specialized complex in North Gyeongsang Province (Andong), is leading the project. Pohang University of Science and Technology, the International Vaccine Institute (IVI), and the Gyeongbuk Institute for Bio-Industry are also participating as co-researchers on specific subprojects.

By precisely optimizing antigen genes using AI and applying them to the CreOSG vaccine platform, the company aims to secure candidate substances and manufacturing technologies for preventive vaccines against rotavirus and dengue virus. Furthermore, it plans to expand into multivalent vaccine formats that can respond to various viruses. Based on this, certain preclinical trials will also be conducted.

Rotavirus and dengue virus have unstable antigen protein structures, making it difficult for the human immune system to trigger a defensive immune response. These structural issues make vaccine development more challenging, and live vaccines or conventional approaches struggle to address such viral mutations. As a result, AI-based antigen stabilization and optimization technologies are emerging as key alternatives for next-generation vaccine development.

In this vaccine development project, CreOSG will maximize the use of AI to design target antigens that can induce optimal immune responses. After verifying the optimal structure using CryoEM (cryo-electron microscopy), the company expects to enable rapid and effective development of rotavirus and dengue virus vaccines through comprehensive evaluation of vaccine efficacy in animal studies.

Lee Jiho, a professor at Pohang University of Science and Technology, stated, "The integration of AI-based protein design and Cryo-EM structural analysis is a core strategy for next-generation vaccine development. Utilizing structurally stabilized antigens can induce stronger and more precise immune responses, and this project will serve as an important milestone in realizing that potential."

A CreOSG representative emphasized, "With our selection for this national project, we expect full-scale development of rotavirus and dengue virus vaccines, which have significant market potential. We have continuously collaborated with the Gyeongbuk Institute for Bio-Industry and the International Vaccine Institute on various vaccine R&D projects, so rapid development of rotavirus and dengue virus vaccines is possible, and this will accelerate both preclinical toxicity tests and clinical trials."

This content was produced with the assistance of AI translation services.